Emerging Evidence on Balneotherapy and Thermal Interventions in Post-COVID-19 Syndrome: A Systematic Review.

Publication date: Jan 07, 2025

Post-COVID-19 syndrome affects 10-60% of SARS-CoV-2 survivors. While conventional treatments show limited efficacy, emerging evidence suggests the potential benefits of balneotherapy in managing persistent symptoms. We aimed to systematically evaluate the efficacy and safety of balneotherapy and thermal treatment interventions in treating post-COVID-19 syndrome. We conducted a systematic review following PRISMA guidelines, searching major databases through 31 January 2024. Eligible studies included randomized controlled trials, observational studies, and pilot studies investigating thermal spa treatments for adult post-COVID-19 patients. Analysis of six eligible studies (n = 617) demonstrated significant therapeutic benefits. The largest cohort (n = 159) showed 47% reduction in fatigue and 48% reduction in muscle pain (p < 0. 01). Comprehensive spa therapy achieved complete symptom resolution in one-third of the participants. Combined spa-ubiquinol therapy improved metabolic function (p < 0. 05). All interventions demonstrated favorable safety profiles. Preliminary evidence suggests balneotherapy effectively ameliorates multiple post-COVID-19 symptoms, particularly fatigue, muscle pain, and exercise intolerance. While safety profiles appear favorable, larger randomized controlled trials with standardized protocols are needed to establish definitive therapeutic recommendations.

Open Access PDF

Concepts Keywords
Balneotherapy balneotherapy
Basel hydrotherapy
Healthcare long COVID-19 syndrome
Intolerance post-acute COVID-19 sequelae
respiratory rehabilitation
spa therapy
thermal therapy

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Syndrome
disease IDO symptom
drug DRUGBANK Ubiquinol
disease MESH fatigue muscle
disease MESH Long Covid
drug DRUGBANK Coenzyme M
drug DRUGBANK L-Aspartic Acid
disease MESH sequelae
disease IDO acute infection
disease IDO entity
disease MESH dyspnea
disease MESH cognitive impairment
disease MESH inflammation
disease MESH chronic conditions
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
drug DRUGBANK Water
disease MESH pain thresholds
disease IDO intervention
disease IDO process
drug DRUGBANK Oxygen
disease MESH Depression
drug DRUGBANK Chloride ion
disease IDO quality
disease IDO cell
disease MESH stroke
disease MESH COPD
disease MESH obesity
disease MESH respiratory infections
disease IDO susceptibility
disease MESH psychological stress
disease MESH physiological stress
disease MESH tachycardia
disease IDO replication
disease MESH tumor
drug DRUGBANK Sulpiride
drug DRUGBANK Efavirenz
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH fibromyalgia
disease MESH rheumatic diseases
drug DRUGBANK Alpha-1-proteinase inhibitor
pathway REACTOME Immune System
disease MESH Musculoskeletal Diseases
disease MESH osteoarthritis
drug DRUGBANK Hydrocortisone
disease MESH musculoskeletal pain
disease MESH knee osteoarthritis
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH Respiratory Diseases
disease IDO blood
disease MESH low back pain
disease MESH Infection
disease MESH Periodontitis

Original Article

(Visited 2 times, 1 visits today)